F S&P 500
5,254.00 +15.00 (+0.29%) F Dow Jones
39,617.00 +81.00 (+0.20%) F Nasdaq
18,281.75 +67.25 (+0.37%) E-mini Russell 2000 Index Futur
2,091.80 +7.70 (+0.37%) Petróleo
79.80 +0.54 (+0.68%) Oro
2,379.10 +38.80 (+1.66%)
Keros Therapeutics, Inc. (KROS)
Fuera de horario:
Keros Therapeutics, Inc.
1050 Waltham Street
Suite 302
Lexington, MA 02421
United States
617 314 6297
https://www.kerostx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 141
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jasbir S. Seehra Ph.D. | President, CEO & Director | 1.13M | 158.64k | 1956 |
| Mr. Keith C. Regnante MBA | Chief Financial Officer | 636.11k | 1.22M | 1970 |
| Mr. Christopher Rovaldi M.Sc. | Chief Operating Officer | 784.9k | N/D | 1975 |
| Ms. Esther Cho J.D. | Senior VP, General Counsel & Secretary | N/D | N/D | N/D |
| Ms. Robin Wagner | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Mr. John Oram M.B.A. | Senior Vice President of Program & Portfolio Management | N/D | N/D | N/D |
Descripción
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Keros Therapeutics, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 7; Junta: 8; Derechos del accionista: 7; Compensación: 9.
